Yutaka Fujiwara

Has grant

Head

Aichi Cancer Center

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Yutaka Fujiwara serves as the Head at Aichi Cancer Center in Japan. His research primarily focuses on the treatment and pharmacokinetics of solid tumors, particularly in the context of lung cancer and innovative therapeutic approaches. Recent articles highlight his work on EGFR tyrosine kinase inhibitors, immunotherapy combinations, and the pharmacological assessment of new anticancer agents.

Recent Grants

Grant: Close

小細胞肺癌におけるアムルビシン治療最適化のための効果予測因子の同定

Open Date: 2017-04-01

Close Date: 2020-03-31

Grant: Close

The genomic and epigenomic landscape in thymic carcinoma

Open Date: 2014-04-01

Close Date: 2017-03-31

Grant: Close

Personalized cancer chemotherapy: efficacy and safety based on pharmacokinetics and pharmacogenetics

Open Date: 2013-04-01

Close Date: 2016-03-31

Articles (10)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (3)

Shogo Nomura

Project Lecturer

University of Tokyo

JAPAN

View details

Eiji Iwama

Kyushu University

JAPAN

View details

Naozumi Hashimoto

Nagoya University Graduate School of Medicine

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yutaka Fujiwara

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation

ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors

Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors

Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors

Efficacy of surgery for skin cancers initially suspected to be carcinoma of unknown primary: a retrospective observational study

Successful IMRT and concurrent chemotherapy for a patient with intrathoracic extensive‐stage small cell lung cancer

First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

Collaborators (3)

Shogo Nomura

Eiji Iwama

Naozumi Hashimoto

Make your next move.